PMID- 36091746
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220913
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- 
      and third-line for advanced or metastatic non-small cell lung cancer in China.
PG  - 880280
LID - 10.3389/fphar.2022.880280 [doi]
LID - 880280
AB  - Objective: Domestic PD-1inhibitor tislelizumab has emerged as a promising 
      treatment for Chinese patients with driver-negative advanced or metastatic 
      non-small cell lung cancer (NSCLC). The purpose of our study to evaluate whether 
      tislelizumab is cost-effective as a second- or third-line treatment for this 
      population compared with docetaxel (conventional chemotherapy) and nivolumab 
      (imported PD-1inhibitor), from the perspective of the Chinese healthcare system. 
      Material and Methods: A Markov model with a 3-week Markov cycle and a 30-year 
      time horizon was built to compare the cost-effectiveness of second- or third-line 
      tislelizumab versus docetaxel and nivolumab. Transition probabilities, including 
      disease progression, survival, and adverse events (AEs)-related treatment 
      discontinuation event, were estimated from the clinical trials. Costs and health 
      utilities were collected from local hospitals, public database and published 
      literature. Results: Compared with docetaxel, tislelizumab provided an additional 
      0.33 quality-adjusted life-years (QALYs) (1.37 vs. 1.04 QALYs) at an incremental 
      cost of $9,286 ($23,646 vs. $14,360) for Chinese patients with driver-negative 
      advanced or metastatic NSCLC, resulting in an incremental cost-effectiveness 
      ratio (ICER) of $27,959/QALY under the WTP threshold of $35,663/QALY used in the 
      model. Compared with nivolumab, tislelizumab was associated with a lower cost 
      ($23,646 vs. $59,447) and higher QALYs (1.37 vs. 1.20 QALYs), resulting in its 
      dominance of nivolumab. Conclusion: From the perspective of the Chinese 
      healthcare system, domestic PD-1inhibitor tislelizumab immunotherapy represents a 
      cost-effective treatment strategy compared with conventional docetaxel 
      chemotherapy and imported PD-1inhibitor nivolumab immunotherapy in the treatment 
      of driver-negative advanced or metastatic NSCLC beyond the first-line setting. In 
      the era of "Universal Medical Insurance System", the rational use of domestic 
      anticancer drugs guided by cost-benefit evidence would be an effective means to 
      balance the limited expenditure of medical insurance fund and the growing demand 
      for cancer treatments.
CI  - Copyright (c) 2022 Zhou, Luo, Zhou, Zeng, Wan, Tan and Liu.
FAU - Zhou, Dongchu
AU  - Zhou D
AD  - Department of Pharmacy, The Second Xiangya Hospital of Central South University, 
      Changsha, China.
FAU - Luo, Xia
AU  - Luo X
AD  - Department of Pharmacy, The Second Xiangya Hospital of Central South University, 
      Changsha, China.
FAU - Zhou, Zhen
AU  - Zhou Z
AD  - Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, 
      Australia.
FAU - Zeng, Xiaohui
AU  - Zeng X
AD  - Department of Nuclear Medicine/PET Image Center, The Second Xiangya Hospital of 
      Central South University, Changsha, China.
FAU - Wan, Xiaomin
AU  - Wan X
AD  - Department of Pharmacy, The Second Xiangya Hospital of Central South University, 
      Changsha, China.
FAU - Tan, Chongqing
AU  - Tan C
AD  - Department of Pharmacy, The Second Xiangya Hospital of Central South University, 
      Changsha, China.
FAU - Liu, Qiao
AU  - Liu Q
AD  - Department of Pharmacy, The Second Xiangya Hospital of Central South University, 
      Changsha, China.
LA  - eng
PT  - Journal Article
DEP - 20220825
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9453816
OTO - NOTNLM
OT  - China
OT  - NSCLC
OT  - cost-effectiveness
OT  - docetaxel
OT  - nivoluma
OT  - tislelizumab
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/13 06:00
MHDA- 2022/09/13 06:01
PMCR- 2022/08/25
CRDT- 2022/09/12 04:06
PHST- 2022/02/21 00:00 [received]
PHST- 2022/07/25 00:00 [accepted]
PHST- 2022/09/12 04:06 [entrez]
PHST- 2022/09/13 06:00 [pubmed]
PHST- 2022/09/13 06:01 [medline]
PHST- 2022/08/25 00:00 [pmc-release]
AID - 880280 [pii]
AID - 10.3389/fphar.2022.880280 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Aug 25;13:880280. doi: 10.3389/fphar.2022.880280. 
      eCollection 2022.